CONTENTS 6 News
10 A culture of transparency A new EU policy will require pharmaceutical companies to provide clinical trial data when seeking marketing approval for their drugs. But how will they ensure adequate IP protection while embracing the new culture of transparency? LSIPR reports.
18 14 PlasmaTech: two strings to its bow
It might seem odd for a company to both divide blood plasma and fi ght the side- effects of cancer treatment, but not for PlasmaTech Biopharmaceuticals, which tells LSIPR about how the company does it and also protects its IP.
18 Seeing the future
Google’s new contact lens sensor is just one of the latest eye-based devices that has vast potential in the fi eld of medicine. LSIPR reports.
22 A clash of the courts
The US Supreme Court has heard arguments in the appeal of Teva v Sandoz from the US Court of Appeals for the Federal Circuit. It could fundamentally change how the Federal Circuit reviews patent decisions, says Felicia Boyd of Barnes & Thornburg.
26 Cold feet in Canada 22
The Supreme Court of Canada was expected to bring the Canadian law on utility more into line with other jurisdictions, but those hopes have now received a setback, as Gunars Gaikis of Smart & Biggar/Fetherstonhaugh reports.
30 IPEC: the right forum for life sciences?
The UK Intellectual Property Enterprise Court offers a quick and cheap way to resolve IP disputes, but very few have involved life sciences inventions. Mark Didmon and Simon Curtis of Potter Clarkson ask whether IPEC is an appropriate forum for handling these types of patent disputes.
34 Breaking down barriers
There still are some cultural, legal and procedural barriers that must be overcome before the potential of Brazil’s life sciences sector can be realised, as Gabriel Di Blasi and Mellina Mamede of Di Blasi, Parente & Associados explain.
30 36 Bridging the gap
The Indian Patent Offi ce has issued guidelines aimed at bringing together the intentions of the Patents Act and the Biological Diversity Act, but this has posed serious challenges in obtaining patent protection, say Ranjna Mehta-Dutt and Neha Srivastava of Remfry & Sagar.
38 Genetic resources in Mexico
The current regulations in Mexico provide a legal framework for protecting genetic resources, but the framework for investing in new biotechnology is still not clear. Karla Roxana Aispuro Castro and Mariana González Vargas of Becerril, Coca & Becerril report.
40 Tomatoes and broccoli: patenting plant products 40
www.lifesciencesipreview.com
The EPO’s Enlarged Board of Appeal is about to deliver its long-awaited fi nal decision on the patentability of plants, in the hope that it will at least bring legal certainty to patentees and unfreeze pending appeals. Franz-Josef Zimmer and Markus Grammel of Grünecker report.
Life Sciences Intellectual Property Review Volume 2, Issue 1 5
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44